Catégorie : Non classé

[Press Release] Effectiveness of XAV-19 against SARS-CoV-2 variants

February 1, 2021. # Download our press release (english version) # Télécharger notre communiqué de presse (version française)

[Newsletter] XENONEWS

March 2021 >> Official Xenothera newsletter /Lettre d’information officielle de Xenothera << # Download our newsletter (english version) # Télécharger notre newsletter (version française)

[Press Alert] New step for XENOTHERA and the Nantes University Hospital

December 29, 2020. # Download our press information (english version) # Télécharger notre information presse (version française)

[Newsletter- 11] NEWS/INFOS

November 2020. >> Official news bulletin for XAV-19/Bulletin officiel du XAV-19 << #Télécharger notre newsletter (version française) #

[Infography/Infographie]

November 25, 2020. # VACCINE & TREATMENT # Understanding the differences # Available here # VACCIN & TRAITEMENT # Bien comprendre les différences # Disponible ici

[Newsletter- 10] NEWS/INFOS

October 2020. >> Official news bulletin for XAV-19/Bulletin officiel du XAV-19 << # Télécharger notre newsletter (version française)#

[Newsletter -2] NEWS /INFOS

May 8, 2020. >> Official news bulletin for XAV-19/Bulletin officiel du XAV-19 << Download our newsletter (english version) Télécharger notre newsletter (version française)

[Alerte actualité] Anticorps XAV-19

30 avril 2020 Download the press release / Télécharger le communiqué

COVID19 / XAV-19 : Scientific and medical rationale

Français ci-dessous «  We are convinced that our treatment will be efficient, for medical and scientific reasons today published in international scientific journals, namely by Chinese teams who have worked hard for 4 months, and with whom we have established our first contacts” says Odile Duvaux, MD and CEO of Xenothera Our arguments are the following:…
Lire la suite

Xenothera presents at Toulouse ONCOWEEK 2020

At ONCOWEEK 2020 that will take place in Toulouse on Feb. 3-5, Xenothera will present original data from its Glyco-Humanized Polyclonal Antibodies (GH-pAb) platform. Scientists from Xenothera found that pAbs raised against given tumor cells show specificity, inhibit tumor growth, synergize with immune checkpoint inhibitors and owing to their mechanism of action induce conversion of…
Lire la suite